Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give More Than 350 Flagstaff Children New Winter Coats[9:30:00 AM ET]FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give 350 Bay City Children New Winter Coats[9:30:00 AM ET]APH$82.27+4.06(+5.18%)Industrial Growth Partners Announces Sale of AdvancedPCB Industrial Growth Partners ("IGP") is pleased to announce that it has entered into a definitive agreement to sell AdvancedPCB Holdings, LLC...[9:27:00 AM ET]BLGO$0.070.00(0.00%)BioLargo Introduces barebird, a Company-Owned Brand, Reuniting Key Teams Behind Pooph's Consumer Market Success[9:25:00 AM ET]TWOSF$0.24-0.00(-0.04%)T2 Metals to Attend the 52nd Annual New Orleans Investment Conference[9:25:00 AM ET]MOB$3.290.00(0.00%)Mobilicom to Showcase Cybersecure Portfolio Highlighting Newly Launched SwarmiX at ARC WEPTAC Conference[9:22:00 AM ET]COSM$0.25+0.01(+4.24%)Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target[9:20:00 AM ET]MGN$2.83-0.23(-7.52%)Megan Holdings Limited Announces Pricing of Up to $7.5 Million Follow-on Public Offering[9:20:00 AM ET]ELS$58.63-0.87(-1.45%)ELS Declares Fourth Quarter 2026 Dividend On October 27, 2026, the Board of Directors of Equity LifeStyle Properties, Inc. (NYSE: ELS) (referred to herein as "we," "us," and "our") declared a ...[9:18:00 AM ET]GSAT$83.93+0.03(+0.04%)XCOM RAN Wins the Gold Stevie® 2026 Award for Technology Excellence[9:16:00 AM ET]CYAB$0.13-0.00(-1.66%)Cyabra Finds Coordinated Inauthentic Activity in Five of Six Competitive Midterm Races, Affecting Candidates from Both Parties[9:15:00 AM ET]AIBT$0.000.00(0.00%)AIBotics Provides PHILL ROBOT™ Manufacturing Update as 3DX Industries Supports Five-Unit Pilot[9:15:00 AM ET]LGVN$1.79+0.06(+3.42%)Longeveron Announces Engagement of Lucid Capital Markets[9:15:00 AM ET]QNC$1.12+0.03(+2.75%)Quantum eMotion to Showcase Quantum-Safe Cybersecurity Portfolio at World Quantum Cannes Festival November 17-18, 2026[9:15:00 AM ET]OSRH$0.20-0.00(-0.30%)OSR Health Provides Shareholder Update Following Nasdaq Panel Decision[9:15:00 AM ET]CWBHF$0.23-0.01(-4.68%)Charlotte's Web to Report Third Quarter 2026 Results on November 12[9:14:00 AM ET]

GERN · NASDAQ

Geron Corporation

$0.99 -0.15 (-13.16%)

Company overview

Geron Corporation is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company develops imetelstat, a telomerase inhibitor currently in Phase 3 clinical trials that inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron was incorporated in 1990 and is headquartered in Foster City, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$636M
Employees
229
Headquarters
Foster City, CA
Website
geron.com
CEO
Harout Semerjian
Listed
July 31, 1996
P/E
-9.49
Dividend yield
0.00%

Company financials

Revenue
$196M
Gross profit
$170M
Operating income
-$37.4M
EBITDA
-$40.7M
Net income
-$69.6M
EPS
-$0.10
Total assets
$534M
Total debt
$252M
Gross margin
86.59%
Net margin
-35.48%
Earnings yield
-10.54%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

1.051.231.401.581.75
GERN 1D NASDAQ O1.16H1.19L1.14C1.15-0.00 (-0.43%)Vol1.42M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
GERNGeron Corporation Stock news Geron discontinues late-stage trial of blood cancer drug Reuters
GERNGeron Corporation Press release Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis GlobeNewswire
GERNGeron Corporation Press release Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 GlobeNewswire
GERNGeron Corporation Press release Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
GERNGeron Corporation Legal Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached... PR Newswire
GERNGeron Corporation Legal Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN Business Wire
GERNGeron Corporation Press release Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia GlobeNewswire
GERNGeron Corporation Press release Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire
GERNGeron Corporation Press release Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewsWire
GERNGeron Corporation Stock news Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands MarketBeat
GERNGeron Corporation Legal Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN GuruFocus
GERNGeron Corporation Legal Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN Business Wire
GERNGeron Corporation Stock news Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands MarketBeat
GERNGeron Corporation Stock news Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? GuruFocus
GERNGeron Corporation Legal Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm PRNewsWire
GERNGeron Corporation Press release Geron to Present at Upcoming Investor Conferences GlobeNewswire
GERNGeron Corporation Stock news ADAR1 Capital Management LLC Invests $647,000 in Geron Corporation $GERN Defense World
GERNGeron Corporation Press release Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewsWire
GERNGeron Corporation Stock news Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis Seeking Alpha
GERNGeron Corporation Stock news Geron Corporation (GERN) Q2 2026 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about Geron Corporation

What does Geron Corporation do?
Geron Corporation is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company develops imetelstat, a telomerase inhibitor currently in Phase 3 clinical trials that inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron was incorporated in 1990 and is headquartered in Foster City, California.
What is GERN's market cap?
Geron Corporation (GERN) is a listed stock with a live quote. The latest market cap on this page is $636M.
Where is Geron Corporation headquartered?
Geron Corporation is headquartered in Foster City, CA.
How do I get GERN news from the API?
Call GET /v1/news?tickers=GERN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does GERN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for GERN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the GERN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs